Physician profile
Ana L Cabrera
NPI 1699316166
$1,700.83
in general payments reported to CMS, 2019-2025
18 companies · $360 in 2025
The $360 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $467 · 2023: $292 · 2024: $581 · 2025: $360.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,234.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,234.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $274.65 | 2022-2024 | Repatha, Otezla |
| Stryker Corporation | $250.74 | 2022 | |
| Phathom Pharmaceuticals, INC. | $237.12 | 2024-2025 | Voquezna |
| Bayer Healthcare Pharmaceuticals INC. | $151.56 | 2023-2024 | |
| Madrigal Pharmaceuticals | $150.00 | 2024 | Rezdiffra |
| Lilly USA, LLC | $147.60 | 2022-2025 | Mounjaro |
| Abbvie INC. | $122.72 | 2022-2025 | |
| Ipsen Biopharmaceuticals, INC | $102.59 | 2024 | Iqirvo |
| Teva Pharmaceuticals USA, INC. | $42.44 | 2024 | Austedo Xr |
| Boston Scientific Corporation | $35.19 | 2025 | Avvigo Guidance System |
| Alk-Abello, INC | $33.89 | 2024 | Ragwitek, Odactra, Grastek |
| Neurocrine Biosciences, INC. | $25.54 | 2025 | |
| Astrazeneca Pharmaceuticals LP | $25.12 | 2025 | Farxiga |
| Paratek Pharmaceuticals, INC. | $25.00 | 2024 | Nuzyra |
| Otsuka America Pharmaceutical, INC. | $23.85 | 2024 | Abilify Asimtufii, Abilify Maintena |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $19.48 | 2022 | |
| Cranial Technologies, INC | $17.43 | 2022 | |
| Dexcom, INC. | $15.91 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ana Cabrera listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.